Literature DB >> 32151943

Innovated formulation of TCM pangolin scales to develop a nova therapy of rheumatoid arthritis.

Huiqing Lv1, Zihan Li2, Zhijun Xie3, Xuanming Hu4, Haichang Li3, Jing Sun5, Xuezhi Chen6, Chengping Wen7.   

Abstract

Pangolin scale (PS) is a traditional Chinese medicine (TCM) for treating rheumatic arthritis (RA), and diverse medicinal formulations and therapeutic properties of PS have proved great potential to supplement conventional treatments in integrative medicine-based strategies. However, few studies have investigated how different PS formulations can impact the management of RA. Herein, we developed an innovative formulation of PS processed with vinegar (PSP) and evaluated it by comparing with the traditional decoction of PS (PSD) and non-steroidal anti-inflammatory drug (NASID) (i.e., meloxicam) in a RA Sprague Dawley rat model, which is induced with a complete Freund's adjuvant (CFA). The anti-inflammatory activities were evaluated by paw edema measurement, arthritic score, histopathological examination, pro-inflammatory cytokines (IL-1β and TNF-α) production and the whole blood viscosity. PSP treatments (249.0 mg/kg.bw) from day 14-42 alleviated paw edema (P < 0.001), arthritic index (score 0-1.5) and the inflammatory cell infiltration in the ankle joint, which may be attributed to inhibiting the production of TNF-α (P < 0.01) and IL-1β (P < 0.05) in the serum. Although PSP is with fewer efficacies than meloxicam, it outperformed traditional formulation PSD (830 mg/kg.bw) in all above mentioned metrics. Furthermore, PSP exhibited a unique effect on reducing whole blood viscosity (P < 0.05) unobserved in meloxicam intervention. The present study demonstrates that PSP showed more efficient anti-inflammatory activity than PSD in CFA-induced RA rats, possibly due to the presence of higher levels of active ingredients. Thus, PSP may be a promising therapy for anti-inflammation in RA and can be integrated with conventional treatments, particularly for long-term RA management in an integrative treatment strategy.
Copyright © 2020. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Complete Freund’s adjuvant; Formulation development; Pangolin scale; Rheumatic arthritis

Mesh:

Substances:

Year:  2020        PMID: 32151943     DOI: 10.1016/j.biopha.2020.109872

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Comparison of the efficacy and safety indicators of DMARDs for rheumatoid arthritis: A network meta-analysis.

Authors:  Zunlian Wang; Min Huang; Bin Yu; Yilan Huang; Silin Zheng; Xuping Yang; Hong Ning
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

Review 2.  A Systematic Review of the Anti-Inflammatory and Immunomodulatory Properties of 16 Essential Oils of Herbs.

Authors:  Xu Zuo; Yinuo Gu; Chao Wang; Jinrong Zhang; Jing Zhang; Guoqiang Wang; Fang Wang
Journal:  Evid Based Complement Alternat Med       Date:  2020-12-07       Impact factor: 2.629

3.  Catalpol Inhibits Tregs-to-Th17 Cell Transdifferentiation by Up-Regulating Let-7g-5p to Reduce STAT3 Protein Levels.

Authors:  Yuxi Di; Mingfei Zhang; Yichang Chen; Ruonan Sun; Meiyu Shen; Fengxiang Tian; Pei Yang; Feiya Qian; Lingling Zhou
Journal:  Yonsei Med J       Date:  2022-01       Impact factor: 2.759

4.  Comparison of Pharmacokinetic Profiles of 14 Major Bioactive Components in Normal and Arthritic Model Rats after Oral Administration of Angelicae pubescentis Radix by UPLC-MS/MS.

Authors:  Ajiao Hou; Huan Yu; Song Wang; Jiaxu Zhang; Xuejiao Wang; Senwang Zheng; Liu Yang; Haixue Kuang; Hai Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-16       Impact factor: 2.650

Review 5.  Medicine in motion: Opportunities, challenges and data analytics-based solutions for traditional medicine integration into western medical practice.

Authors:  C Jansen; J D Baker; E Kodaira; L Ang; A J Bacani; J T Aldan; L M N Shimoda; M Salameh; A L Small-Howard; A J Stokes; H Turner; C N Adra
Journal:  J Ethnopharmacol       Date:  2020-10-21       Impact factor: 4.360

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.